In multiple SCLC xenograft models, RYZ101 significantly inhibited tumor growth and prolonged survival, with deeper responses, including sustained regression, observed in the models with higher SSTR2 level. The anti-tumor effect was further enhanced when combining RYZ101 with carboplatin and etoposide at clinically relevant doses....In summary, RYZ101 is a first-in-class, highly potent, α-emitting radiopharmaceutical therapy being developed for the treatment of SSTR+ solid tumors. Preclinical data demonstrate the potential of RYZ101 for the treatment of patients with SSTR+ SCLC.